Also listed on Genewave, an earlier holder on the record. The recorded assignments below show how it moved.
Collateral for a security interest recorded Apr 8, 2026 (Royal Bank of Canada).
Term ends Jan 8, 2032 · High confidence
20-year base term ends Dec 28, 2031
Held by Gen-Probe Incorporated
Filed Apr 30, 2019 as application 16/398,890 · Granted Sep 30, 2025
Base term plus 99 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
2011
2032
Clock starts
Dec 28, 2011
Dec 28, 2011
Term ends
Jan 8, 2032
Jan 8, 2032
Granted
Sep 30, 2025
Sep 30, 2025
base term
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
99
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 11,415,514.
0 of 1
Maintenance fees paid
One maintenance fee can end this term early, the one due 3.5 years from grant; the next one's grace period runs past the term end. This counts it if the record shows it paid.
6
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 99 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 0 of 1 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Dec 28, 2011, when application PCT/FR2011/053208, the earliest non-provisional in its chain, was filed (this one was filed Apr 30, 2019) | Dec 28, 2031 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +99 days, USPTO patent term adjustment record | Apr 5, 2032 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 11,415,514) | capped to Jan 8, 2032 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 1 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jan 8, 2032 | High confidence |
This family
| US 10,184,891 | In force Apr 2033 | Apr 2033 |
| US 11,415,514 | In force Jan 2032 | Jan 2032 |
| US 12,429,422 | this patent Jan 2032 | Jan 2032 |
| Application 17/818,612 | Abandoned not computed | not computed |
| US 12,117,397 | In force Dec 2031 | Dec 2031 |
5 of 6 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Apr 30, 2019 Reel 49036, frame 192 | Weisbuch, Claude; Martinelli, Lucio; Benisty, Henri; Schafauer, Christof; Sagarzazu, Gabriel; Gacoin, Thierry; Bedu, Mélanie | Genewave | Assignment of Assignor's Interest |
| Oct 3, 2024 Reel 68787, frame 15 | Genewave SAS | Mobibiag Oy | Assignment of Assignor's Interest |
| Oct 3, 2024 Reel 68787, frame 41 | Mobidiag Oy | Gen-Probe Incorporated | Assignment of Assignor's Interest |
| Apr 8, 2026 Reel 75462, frame 440 | Biotheranostics, Inc.; Gen-Probe Incorporated; Gen-Probe Prodesse, Inc.; Cytyc Corporation; Suros Surgical Systems, Inc.; Gynesonics, Inc.; Bolder Surgical, LLC; Faxitron Bioptics, LLC; Health Beacons, Inc.; Hologic, Inc. | Royal Bank of Canada, as Collateral Agent | Security Interest |
| Apr 8, 2026 Reel 75926, frame 339 | Biotheranostics, Inc.; Gen-Probe Incorporated; Gen-Probe Prodesse, Inc.; Cytyc Corporation; Suros Surgical Systems, Inc.; Gynesonics, Inc.; Bolder Surgical, LLC; Faxitron Bioptics, LLC; Health Beacons, Inc.; Hologic, Inc. | Citibank, N.A., as Collateral Agent | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Jan 2032
Term ends Jan 8, 2032. Maintenance fees still fall due before then
Note
The 99 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 11,415,514.
Citations
0
later US patents cite this one
Fewer than half of the utility patents granted in 2025 in our data have been cited yet, so we show the count and do not rank on it.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.